Evidence map›Paper›PMID 38222816›Full record

ArticleJOR spine2024

Differential efficacy of two small molecule PHLPP inhibitors to promote nucleus Pulposus cell health.

Changli Zhang, Madeleine D Gordon, Katherine M Joseph, Martha E Diaz-Hernandez, Hicham Drissi, Svenja Illien-Jünger

Open access · goldAbstract read
In one paragraph

Article in JOR spine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. PHLPP is neither a Phosphatase nor a Tumor Suppressor.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  3. Article
  4. Aging · 2025
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Changli ZhangDepartment of Orthopaedics Emory University School of Medicine Atlanta Georgia USA.ORCID https://orcid.org/0000-0002-1170-0374
Madeleine D GordonDepartment of Orthopaedics Emory University School of Medicine Atlanta Georgia USA.ORCID https://orcid.org/0009-0004-4772-285X
Katherine M JosephDepartment of Orthopaedics Emory University School of Medicine Atlanta Georgia USA.
Martha E Diaz-HernandezDepartment of Orthopaedics Emory University School of Medicine Atlanta Georgia USA.
Hicham DrissiDepartment of Orthopaedics Emory University School of Medicine Atlanta Georgia USA.
Svenja Illien-JüngerDepartment of Orthopaedics Emory University School of Medicine Atlanta Georgia USA.ORCID https://orcid.org/0000-0001-9895-0693
Emory University · USGeorgia Institute of Technology · US

Funding

Targeting PHLPP to treat interval disc degeneration using surgical and drug delivery methodsR01AR078908 · NIAMS · EMORY UNIVERSITY · PI Svenja Illien-Junger · 2022 to 2026
$1.9M
Targeting PHLPP1 to Inhibit Progression of Intervertebral Disc DegenerationR21AR072222 · NIAMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ILLIEN-JUNGER, SVENJA · 2018 to 2019
$401k
NIAMS NIH HHS R01 AR078908NIAMS NIH HHS R21 AR072222
6 · The paper itself

Abstract

Background: Intervertebral disc (IVD) degeneration is associated with chronic back pain. We previously demonstrated that the phosphatase pleckstrin homology domain and leucine-rich repeat protein phosphatase (PHLPP) 1 was positively correlated with IVD degeneration and its deficiency decelerated IVD degeneration in both mouse IVDs and human nucleus pulposus (NP) cells. Small molecule PHLPP inhibitors may offer a translatable method to alleviate IVD degeneration. In this study, we tested the effectiveness of the two PHLPP inhibitors NSC117079 and NSC45586 in promoting a healthy NP phenotype. Methods: Tail IVDs of 5-month-old wildtype mice were collected and treated with NSC117079 or NSC45586 under low serum conditions ex vivo. Hematoxylin & eosin staining was performed to examine IVD structure and NP cell morphology. The expression of KRT19 was analyzed through immunohistochemistry. Cell apoptosis was assessed by TUNEL assay. Human NP cells were obtained from patients with IVD degeneration. The gene expression of KRT19, ACAN, SOX9, and MMP13 was analyzed via real time qPCR, and AKT phosphorylation and the protein expression of FOXO1 was analyzed via immunoblot. Results: In a mouse IVD organ culture model, NSC45586, but not NSC117079, preserved vacuolated notochordal cell morphology and KRT19 expression while suppressing cell apoptosis, counteracting the degenerative changes induced by serum deprivation, especially in males. Likewise, in degenerated human NP cells, NSC45586 increased cell viability and the expression of KRT19, ACAN, and SOX9 and reducing the expression of MMP13, while NSC117079 treatment only increased KRT19 expression. Mechanistically, NSC45586 treatment increased FOXO1 protein expression in NP cells, and inhibiting FOXO1 offset NSC45586-induced regenerative potential, especially in males. Conclusions: Our study indicates that NSC45586 was effective in promoting NP cell health, especially in males, suggesting that PHLPP plays a key role in NP cell homeostasis and that NSC45586 might be a potential drug candidate in treating IVD degeneration.

Indexed as

FOXO1intervertebral disc degenerationNSC117079NSC45586nucleus pulposusPHLPPsmall molecule PHLPP inhibitor

Identifiers

PMID38222816
PMCPMC10782076
OpenAlexW4389345241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.